(Sharecast News) - MaxCyte announced the signing of a strategic platform licence agreement with TG Therapeutics on Wednesday, granting the biopharmaceutical company access to its 'Flow Electroporation' technology and 'ExPERT' platform to support the development and commercialisation of Azer-cel, an allogeneic CD19 CAR T cell therapy for autoimmune diseases.
The AIM-traded firm said that under the agreement, TG Therapeutics would obtain non-exclusive rights to use MaxCyte's platform for research, clinical development, and commercialisation.
In return, MaxCyte would receive annual licensing fees and programme-related revenue.
TG Therapeutics recently acquired worldwide rights to Azer-cel from Precision BioSciences, and received US Food and Drug Administration (FDA) clearance for an investigational new drug application in progressive forms of multiple sclerosis.
The company said it was planning to initiate a phase one trial this year.
MaxCyte described its ExPERT platform as a next-generation electroporation technology designed to enable high-efficiency cell engineering at clinical and commercial scale.
"By leveraging our commercially validated cell-engineering platform and optimized T cell manufacturing workflow, TG Therapeutics is advancing toward their phase one clinical trial for the application of azer-cel in progressive forms of MS," said MaxCyte president and chief executive officer Maher Masoud.
"Our technology has been integral to the manufacturing of allogeneic T cell immunotherapies and was efficiently transferred from Precision BioSciences when TG Therapeutics obtained global rights for azer-cel for autoimmune diseases in January 2024.
"With our new partnership, we will continue to support the development of azer-cel to expand the application to autoimmune diseases."
At 0816 GMT, shares in MaxCyte were up 0.74% at 342.5p.
Reporting by Josh White for Sharecast.com.
MaxCyte (MXCT)
